Non Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer

标题 用于诊断临床显著前列腺癌的非侵入性生物标志物 项目概要/摘要 尽管许多新诊断的前列腺癌（PC）的自然史是惰性的， 大多数男性仍然接受具有相关副作用和成本的初级治愈性治疗， 即过度治疗显然需要制定和执行 本地化PC的新管理策略，如果建立在此基础上， 准确评估疾病状态以及惰性与侵袭性的可能性 行为该提案将检验以下假设：指示不良PC的生物标志物 可以在以下患者的尿液中可重复地检测特征（例如高格里森模式）： 男人与PC我们进一步假设，一组非侵入性尿液的初始采样 生物标志物和随着时间的推移对这些标志物的重复评价将与 前列腺中存在显著与不显著的癌症，因此可以 用于通知监测或进行确定性治疗的决定。那个- 这些假设将通过旨在利用不同前列腺的特定目标进行测试 癌症相关的RNA使用定量尿液分析和多机构的长期研究， 通过伴随生物标本的主动监测管理的男性纵向队列，病理学， 逻辑和临床数据。 这些目标的成功完成将为初步的 和前列腺癌的纵向评估，以便提供准确的治疗信息 局部疾病的决定。

Title Non-Invasive Biomarkers for Diagnosing Clinically Significant Prostate Cancer Project Summary/Abstract Despite the indolent natural history of many newly diagnosed prostate cancers (PC), most men still undergo primary curative therapy with associated side effects and costs, i.e. overtreatment. There is an clear need for the development and implementation of new management strategies for localized PC which would be enhanced if founded upon accurate assessments of disease status and the potential for indolent versus aggressive behavior. This proposal will test the hypothesis that biomarkers indicative of adverse PC characteristics (e.g. high Gleason pattern) can be reproducibly detected in the urine of men with PC. We further hypothesize that initial sampling of a panel of noninvasive urine biomarkers and the repeated evaluation of these markers over time will associate with the presence of significant versus insignificant cancer in the prostate, and thus can be used in informing decisions for surveillance or proceeding with definitive treatment. The- se hypotheses will be tested through specific aims designed to exploit distinct prostate cancer-associated RNAs using quantitative urine assays and a multi-institutional longitu- dinal cohort of men managed by active surveillance with attendant biospecimens, patho- logical, and clinical data. The successful completion of these aims will provide non-invasive tools for the initial and longitudinal assessment of prostate cancers in order to inform accurate treatment decisions for localized disease.